{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T10:53:57Z","timestamp":1791629637922,"version":"4.3.4"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100007113","name":"Arak University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007113","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Reducing bleeding episodes is very important in haematology disorders like von Willebrand disease (<jats:styled-content style=\"fixed-case\">VWD<\/jats:styled-content>) and Glanzmann thrombasthenia (<jats:styled-content style=\"fixed-case\">GT<\/jats:styled-content>). Replacement factors are very expensive although prophylactic drugs are affordable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To study the prophylactic effects of tranexamic acid (<jats:styled-content style=\"fixed-case\">TXA<\/jats:styled-content>) for reduction of bleeding episodes in patients with <jats:styled-content style=\"fixed-case\">VWD<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">GT<\/jats:styled-content> in non\u2010invasive conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A controlled, double\u2010blind before and after single\u2010centre trial was performed in Amir\u2010Kabir Hospital (Arak, Iran). The study was done on 17 patients with <jats:styled-content style=\"fixed-case\">VWD<\/jats:styled-content> and three patients with <jats:styled-content style=\"fixed-case\">GT<\/jats:styled-content> with minimum age of 2 years. Patients were received placebo for 6 months to evaluate the frequency and severity of bleeding and also to record the frequency of use of factor concentrates and platelet transfusion. After that, patients were given oral single dose of TXA 25 mg kg<jats:sup>\u22121<\/jats:sup> day<jats:sup>\u22121<\/jats:sup> for 6 months. The mentioned outcomes were studied and compared between two phases of study. Safety assessment was done in all patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Tranexamic acid caused a significant reduction in number of Grade 1 and Grade 2 bleeding episodes in <jats:styled-content style=\"fixed-case\">VWD<\/jats:styled-content> patients (<jats:italic>P<\/jats:italic> &lt; 0.001 and <jats:italic>P<\/jats:italic> &lt; 0.01 respectively). In addition, <jats:styled-content style=\"fixed-case\">TXA<\/jats:styled-content> therapy was associated with significant decrease in the use of factor concentrates (<jats:italic>P<\/jats:italic> &lt; 0.05). Number of bleeding episodes decreased in <jats:styled-content style=\"fixed-case\">GT<\/jats:styled-content> patients who used <jats:styled-content style=\"fixed-case\">TXA<\/jats:styled-content>; however, difference between two phases of studies was not significant (<jats:italic>P<\/jats:italic> = 0.1). <jats:styled-content style=\"fixed-case\">TXA<\/jats:styled-content> had no effect in the frequency of platelet transfusions in <jats:styled-content style=\"fixed-case\">GT<\/jats:styled-content> patients. <jats:styled-content style=\"fixed-case\">TXA<\/jats:styled-content> therapy was associated with headache, back pain and musculoskeletal pain. No case of allergy or thromboembolic events was seen following treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results suggest that TXA is safe and effective to reduce bleeding and use of factor concentrates in <jats:styled-content style=\"fixed-case\">VWD<\/jats:styled-content> patients. In addition, TXA therapy can decrease bleeding in <jats:styled-content style=\"fixed-case\">GT<\/jats:styled-content> patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.13051","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T16:11:20Z","timestamp":1470154280000},"source":"Crossref","is-referenced-by-count":23,"title":["Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial"],"prefix":"10.1111","volume":"22","author":[{"given":"A.","family":"Eghbali","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology and Oncology Arak University of Medical Sciences Arak Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Melikof","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology Arak University of Medical Sciences Arak Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Taherahmadi","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology Arak University of Medical Sciences Arak Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bagheri","sequence":"additional","affiliation":[{"name":"Cancer Research Center and Department of Pharmacology Semnan University of Medical Sciences Semnan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,8]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"147","article-title":"Hemophilia and von Willebrand's disease","volume":"153","author":"Growe G","year":"1999","journal-title":"Can Med Assoc J"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.2.454.454"},{"key":"e_1_2_9_4_1","first-page":"94","article-title":"Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment","volume":"88","author":"Castaman G","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2009.10.016"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/09537109876951"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1182\/blood.V74.6.1997.1997","article-title":"Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A","volume":"74","author":"Rodeghiero F","year":"1989","journal-title":"Blood"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00886.x"},{"key":"e_1_2_9_9_1","first-page":"1038","article-title":"The international prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention","volume":"100","author":"Poon MC","year":"2015","journal-title":"Haematologica"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.11.012"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00672.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.644849"},{"key":"e_1_2_9_13_1","first-page":"CD001886","article-title":"Anti\u2010fibrinolytic use for minimizing perioperative allogeneic blood transfusion","volume":"16","author":"Henry DA","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12146"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2013.05.036"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.4103\/0259-1162.103378"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60278-X"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199957060-00017"},{"key":"e_1_2_9_19_1","first-page":"CD000249","article-title":"Antifibrinolytics for heavy menstrual bleeding","author":"Lethaby A","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90181-5"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2005.05.002"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.13051","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.13051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.13051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T23:26:37Z","timestamp":1694906797000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.13051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1111\/hae.13051"],"URL":"https:\/\/doi.org\/10.1111\/hae.13051","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}